Difference between revisions of "Classical Hodgkin lymphoma"
Jump to navigation
Jump to search
m (→References) |
|||
| Line 22: | Line 22: | ||
===References=== | ===References=== | ||
| − | *[http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102 Canellos GP, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84.] | + | *[http://www.nejm.org/doi/pdf/10.1056/NEJM199211193272102 Canellos GP, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84.][http://www.ncbi.nlm.nih.gov/pubmed/1383821 PubMed] |
*[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31090 Gianni AM et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin's lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. 2008 ASCO annual meeting. Abstract 8506] | *[http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31090 Gianni AM et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin's lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. 2008 ASCO annual meeting. Abstract 8506] | ||
*[http://jco.ascopubs.org/cgi/content/abstract/22/14/2835 Bonadonna G et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835] | *[http://jco.ascopubs.org/cgi/content/abstract/22/14/2835 Bonadonna G et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835] | ||
Revision as of 01:50, 14 November 2011
ABVD (Doxorubicin (Adriamycin), Bleomycin (Blenoxane), Vinblastine (Velban), Dacarbazine (DTIC) (stage I-IV Hodgkin lymphoma)
- Doxorubicin (Adriamycin) 25 mg/m2 IV D1 & 15
- Bleomycin (Blenoxane) 10 units/m2 IV D1 & 15 (1 unit test dose with cycle 1 doses, 60 minutes prior to remainder of full dose)
- Vinblastine (Velban) 6 mg/m2 IV D1 & 15
- Dacarbazine (DTIC) 375 mg/m2
Q28days x 4-6 cycles based on stage, response, and concurrent therapy.
Supportive medications
Antiemetic risk: high
- Acetaminophen 650 mg PO, 30 minutes prior to chemotherapy.
- Aprepitant (Emend) 125 mg PO on D1 prior to chemotherapy, 80mg PO on D2 & 3
- Ondansetron (Zofran) 8 mg PO, 30 minutes prior to chemotherapy on D1, daily on D2-3
- Dexamethasone 4 mg PO BID on D1-3
- Diphendyramine (Benadryl) 25 mg PO on D1 prior to chemotherapy
Supportive Hydration
- 500 ml NS at KVO rate. Use as running IV for chemotherapy infusion.
Pretreatment monitoring parameters
- CBC with diff, liver function tests, pulmonary function tests with DLCO
References
- Canellos GP, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84.PubMed
- Gianni AM et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin's lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. 2008 ASCO annual meeting. Abstract 8506
- Bonadonna G et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835
- Carde, P et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258
- Canellos GP et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med 1992; 327:1478
- Engert A et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 2007; 25:3495